| INTRODUC TI ON
Pancreatic adenocarcinoma is the sixth most common malignancy in the United States; in Japan it also has a high mortality rate, being the fourth most common cause of cancer death 1 (ganjyoho. Survivin belongs to the inhibitor of apoptosis protein family and is expressed in various types of malignancies, making it an attractive target molecule. 3 We previously identified a human leucocyte antigen (HLA)-A24-restricted antigenic peptide (SVN-2B) from the survivin variant survivin 2B, and reported the efficacy of this peptide for several malignancies. 4 In a phase I trial of peptide vaccination for colorectal cancer, breast cancer, bladder cancer, and oral cancer, we observed both reduction of tumor markers and tumor regression in some cases, indicating that peptide vaccination could be a promising approach for survivin-positive cancer. 5 Furthermore, we undertook a phase I clinical trial using SVN-2B plus α-interferon (IFNα)
for advanced pancreatic cancer. 6 Although the number of cases was limited (n = 6), we observed good immune reaction for the SVN-2B 
| MATERIAL S AND ME THODS

| Patients
| Study design and treatment
This was a multicenter, placebo (used for Arm 3 patients) was prepared as saline mixed with incomplete Freund's adjuvant and emulsified. Interferon-β placebo (used for Arm 2 and Arm 3 patients) was prepared as 1 mL saline.
In
Step 1, patients were treated until diagnosed as having PD according to RECIST-PD or clinically apparent disease progression. In
Step 2, all patients who consented to participate were treated with SVN-2B plus IFNβ until diagnosed with immune-related response SVN-2B (n = 34), or placebo (n = 19 
| Assessment
The expressions of survivin and HLA class I were assessed by IHC staining using tumor tissue specimens as described previously. 6, 10 Tumor size was assessed every 6-8 weeks using computed tomography, with the first assessment occurring 8 weeks after the first treatment. The CTL response was assessed by tetramer assay and ELISpot assay before the trial, after
Step 1, and after Step 2, as described previously. 
| Statistical analysis
We calculated that enrollment of 65 patients (in a ratio of 2:2:1) was required to achieve 73.1% power (α = 0.05) to estimate median sur- 
| RE SULTS
| Patient profiles
The 94 patients in the SVN-2B + IFNβ group and 5 patients in the placebo group before and after administration of SVN-2B + IFNβ in Step 2.
| Efficacy outcome and immune responses
During the study period, none of the enrolled patients received treatment other than peptide vaccinations. There was no statistically significant difference in PFS according to the RECIST criteria across the 3 groups (Figure 2A) respectively; P = .4565).
The disease control rate was evaluated according to the RECIST criteria. Stable disease was observed in 3 of 18 patients in the SVN-2B + IFNβ group, 5 of 15 in the SVN-2B group, and 3 of 11 in the placebo group. There was no significant difference in disease control rate across all groups.
Immune responses were evaluated by tetramer assay and enzyme-linked immunospot (ELISpot) assay using PBMCs from prevaccination and 8 weeks after the first vaccination. SVN-2B
peptide-specific tetramer staining was increased after 8 weeks in the SVN-2B + IFNβ group; however, the difference did not reach statistical significance (P = .071; Figure 2B ). There was no significant difference between pre-and posttreatment in the SVN-2B group or the placebo group (P = .9545 and P = .7947, respectively). The ELISpot assay revealed that SVN-2B peptide-specific IFNγ spots were significantly increased after treatment in the SVN-2B + IFNβ group (P = .0245), and IFNγ spots were increased in the SVN-2B group, but this did not reach statistical significance group, the increase in tetramer staining also was not significantly higher than that in the placebo group (P = .5496). In the ELISpot assay, the increases in SVN-2B peptide-specific IFNγ spots were not significantly larger in the SVN-2B + IFNβ group or the SVN-2B group compared with the placebo group (P = .0849 and P = .5892, respectively).
In an exploratory analysis to investigate immunological effects during the period after Step 2 (the cases are summarized in Table   S1 ), tetramer-positive cells were significantly increased at 8 weeks after
Step 2 compared with before Step 1 (P = .0347) and before
Step 2 (P = .0190) in the SVN-2B + IFNβ group, whereas there was no difference in the placebo group ( Figure 2D ). In the ELISpot assay, there was no significant difference between 8 weeks after
Step 2 and before Step 1 ( Figure 2E) . A very small number of SVN-2B peptide-specific IFNγ spots were observed before Step 1 in the SVN-2B + IFNβ group, but some patients had a large num- 
| Safety
| D ISCUSS I ON
In this study, a 3-armed double-blinded placebo-controlled rand- In summary, we show that SVN-2B + IFNβ peptide vaccination therapy is safe and feasible for patients with pancreatic cancer, and
IFNβ is a promising adjuvant for peptide vaccination therapy. Longer treatments with SVN-2B + IFNβ could be beneficial. 
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